	{{#each Dates}}				
		{{#Event}}	
		<div class="block spotblock spot grid-1-3 event--link" data-date="{{month}}" data-location="{{location}}" data-disease="{{disease}}">
            <div class="spotContainer visual headingColor-color2 headingAlignment-left headingStyle-normal iconColor-color1 textColor-color1 textAlignment-left textStyle-normal linkColor-color1 backgroundColor-color7 spotLayout-topimage trigger-change" itemscope="" itemtype="http://schema.org/CreativeWork">
                <div class="content {{bg}} content_310">
                    <div class="content-restrict" style="word-wrap: break-word;">
                        <div itemprop="text">
                            <div class="event_spot_block red">
                                <div class="header">
                                    <h4 class="underline">{{start-date}}</h4>
                                    <h4 class="underline">{{address}}</h4>
                                    <h4>{{area}}</h4>
                                </div>
                                <h2 class="title" itemprop="headline"><a class="eventLink" href="{{link}}">{{title}} <span>&#9654;</span></a></h2>
                            </div>
                        </div>
                    </div>

                </div>
            </div> 
        </div>
						
		{{/Event}}	
	{{/each}}


<div class="tabArea" id="halfWidthTabs">
<div class="tabs tabsHalfWidth">
<ul>
<li><a class="active" href="#ITP">ITP</a></li>
<li><a href="#SAA">SAA</a></li>
</ul>
<div style="clear: both; line-height: 0; font-size: 0;">&nbsp;</div>
</div>
<div class="tabContent active">
<p style="margin: 0 0 20px 0;"><img class="scale-with-grid" alt="" src="/siteassets/gb-portal/therapy-areas/haematology/itp/img/revoladeimagetwo.jpg" /></p>
<p style="font-size: 10px; line-height: 14px; margin: 0;">Do not exceed a maximum dosage of 75 mg/day.<sup>1</sup><br /> * For patients taking 25 mg REVOLADE once every other day, increase dose to 25 mg once daily.<sup>1</sup><br /> † For patients taking 25 mg REVOLADE once daily, consideration should be given to dosing at 12.5 mg once daily or alternatively at a dose of 25 mg once every other day.<sup>1</sup></p>
</div>
<div class="tabContent">
<p style="margin: 0 0 20px 0;"><img class="scale-with-grid" alt="" src="/siteassets/gb-portal/therapy-areas/haematology/itp/img/revoladeimagethree.jpg" /></p>
<p style="font-size: 10px; line-height: 14px; margin: 0;">Do not exceed a maximum dosage of 150 mg/day.<sup>1</sup><br>* For patients taking 25 mg REVOLADE once every other day, increase dose to 25 mg once daily.1<sup>1</sup><br>† For patients taking 25 mg REVOLADE once daily, consideration should be given to dosing at 12.5 mg once daily or alternatively at a dose of 25 mg once every other day.<sup>1</sup></p>
</div>
</div>







<p><strong>Patients:</strong></p>
<ul>
<li>Age: ≥18 years</li>
<li>Diagnosis: chronic ITP (defined as >6 months’ duration with baseline platelet counts <30,000/μL)</li>
<li>Previous treatment: patients had responded to 1 or more previous ITP treatments</li>
<li>Splenectomy status: splenectomised or non-splenectomised</li>
</ul>
<p><strong>Number of patients:</strong></p>
<ul>
<li>197 patients randomised (2:1)</li>
<li>Revolade + local standard of care: n=135</li>
<li>Placebo + local standard of care: n=62</li>
</ul>
<p><strong>Revolade treatment regimen:</strong></p>
<ul>
<li>Revolade starting dose: 50 mg/day</li>
<li>Dose modifications were made on the basis of individual platelet response (increases to a nmaximum of 75 mg/day and dose decreases to 25 mg/day)</li>
</ul>
<p><strong>Treatment duration:</strong></p>
<ul>
<li>6 months</li>
</ul>


<p><strong>Primary endpoint:</strong></p>
<ul>
<li>Odds of response (defined as platelet count of 50,000–400,000/μL) to Revolade versus placebo over 6 months of treatment</li>
</ul>
<p><strong>Secondary endpoints:</strong></p>
<ul>
<li>Median platelet count</li>
<li>Proportion of patients responding at ≥75% of assessments</li>
<li>Mean cumulative weeks of response</li>
<li>Mean maximum weeks of continuous response</li>
<li>Bleeding symptoms</li>
<li>Reduction of baseline treatment for ITP</li>
<li>Use of rescue medicine</li>
</ul>
<p><strong>Results (primary endpoint)</strong></p>
<ul>
<li>The odds of responding were greater in patients in the Revolade group compared with those in the placebo group throughout the 6-month treatment period (odds ratio: 8.2, 99% CI: 3.59–18.73; p<0.0001)</li>
</ul>










